Xencor

^{Priced, Nasdaq: XNCR}

Biotech developing antibodies for severe autoimmune/allergic diseases and cancer.

Industry: Health Care

First Day Return: +51.6%

XNCR

Biotech developing antibodies for severe autoimmune/allergic diseases and cancer.

IPO News for Xencor

Anitbody biotech Alder BioPharmaceuticals files for a $115 million IPO 03/19/14
US IPO Recap: Hilton and eleven others set terms 12/09/13
Xencor prices IPO at $5.50, at lower revised share price 12/03/13

IPO Data
IPO Date	12/02/2013
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$70
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Website www.xencor.com
Headquarters	Monrovia, CA, United States
Founded	1997
Employees at IPO	31

IPO News for Xencor

Anitbody biotech Alder BioPharmaceuticals files for a $115 million IPO 03/19/14
US IPO Recap: Hilton and eleven others set terms 12/09/13
Xencor prices IPO at $5.50, at lower revised share price 12/03/13

Xencor (XNCR) Performance